NEWTOWN, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws Pharma, " "Traws" or "the Company"))), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the final results of its 92-patient Phase 2a study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in subjects with mild-to-moderate COVID-19, and the completion of a bridging study of a compressed tablet formulation of tivoxavir marboxil (TXM), its investigational once-monthly antiviral for seasonal and pandemic influenza prophylaxis.